SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-008780
Filing Date
2022-05-13
Accepted
2022-05-13 17:00:27
Documents
70
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20220331x10q.htm   iXBRL 10-Q 1471930
2 EX-31.1 otlk-20220331xex31d1.htm EX-31.1 9601
3 EX-31.2 otlk-20220331xex31d2.htm EX-31.2 12097
4 EX-32.1 otlk-20220331xex32d1.htm EX-32.1 9498
  Complete submission text file 0001558370-22-008780.txt   6954250

Data Files

Seq Description Document Type Size
5 EX-101.SCH otlk-20220331.xsd EX-101.SCH 45460
6 EX-101.CAL otlk-20220331_cal.xml EX-101.CAL 51440
7 EX-101.DEF otlk-20220331_def.xml EX-101.DEF 224944
8 EX-101.LAB otlk-20220331_lab.xml EX-101.LAB 378374
9 EX-101.PRE otlk-20220331_pre.xml EX-101.PRE 353884
64 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20220331x10q_htm.xml XML 1313777
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 22923742
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences